nonmetastatic crpc: considerations for apalutamide
Published 6 years ago • 898 plays • Length 4:36Download video MP4
Download video MP3
Similar videos
-
5:20
apalutamide in treating nonmetastatic crpc
-
1:10
dr. gomella on the fda approval of apalutamide for nonmetastatic crpc
-
4:53
apalutamide: a next-gen agent for nonmetastatic crpc
-
0:44
dr. wise on the fda approval of apalutamide in non-metastatic crpc
-
5:05
castrate resistant, non-metastatic prostate cancer (m0 state) | prostate cancer staging guide
-
1:36:21
common dilemmas in prostate cancer detection and management
-
29:47
challenging cases in advanced prostate cancer: nmcrpc
-
6:51
understanding nonmetastatic crpc: an overview
-
6:50
ep. 6: identifying nonmetastatic crpc
-
4:41
darolutamide’s role in treating nonmetastatic crpc
-
3:06
titan trial
-
1:23
dr. saad on the safety profile of apalutamide in m0crpc
-
1:45
dr. choudhury on antiandrogen treatment selection in nonmetastatic crpc
-
1:54
dr. plimack discusses trials investigating apalutamide, enzalutamide in m0 crpc
-
1:19
nonmetastatic crpc: meeting an unmet need
-
1:46
dr. saad on the clinical impact of apalutamide in nmcrpc
-
2:00
dr. shore on the tolerability of darolutamide in nonmetastatic crpc
-
1:31
spartan vs. prosper: apalutamide or enzalutamide for nmcrpc?
-
5:04
fda approved agents for non-metastatic crpc
-
0:57
dr. agarwal on the tolerability of apalutamide in mcspc
-
1:09
considerations for apalutamide versus enzalutamide in prostate cancer treatment